A Palmitoylethanolamide (PEA) and Magnesium Based Product (PEAMag) Reduces the Pain and Improves Quality of Life in Patients Affected by Acute and Chronic Pelvic Pain

Abstract

Aims: To assess the analgesic efficacy of a Palmitoylethanolamide and Magnesium based product (PEAMag) on acute and chronic pelvic pain due to different causes, such as CPPS, acute and chronic prostatitis, acute and recurrent cystitis and bladder stones. Methods: A pilot, open-label, prospective, monocentric study was carried out involving 32 patients treated with PEAMag sticks administered orally sublingual for a period of 3 months. Pelvic pain was evaluated using the Visual Analogue Scale (VAS score) and Quality of Life (QoL) associated with pelvic pain using number 9 domain (Quality of Life) of the Italian version of the NIH-CPSI scale. Results: A significant and progressive reduction in pain intensity after 1 month of treatment with PEAMag (p<0.001) and after 3 months of treatment (p<0.001) and a significant improvement in Quality of Life after 1 month of treatment (p<0.0001) and after 3 months of treatment (p<0.001) was observed. The results show also improvements from one month after treatment to 3 months after treatment. Conclusion: These data highlight the potential benefit of PEAMag in patients with varying nature and intensity acute and chronic pelvic pain and confirm the good safety profile of PEA and magnesium based product.